[go: up one dir, main page]

GT200900139A - Metodos para el tratamiento del abuso, adiccion y dependencia del alcohol - Google Patents

Metodos para el tratamiento del abuso, adiccion y dependencia del alcohol

Info

Publication number
GT200900139A
GT200900139A GT200900139A GT200900139A GT200900139A GT 200900139 A GT200900139 A GT 200900139A GT 200900139 A GT200900139 A GT 200900139A GT 200900139 A GT200900139 A GT 200900139A GT 200900139 A GT200900139 A GT 200900139A
Authority
GT
Guatemala
Prior art keywords
alcohol
addiction
abuse
dependence
treatment
Prior art date
Application number
GT200900139A
Other languages
English (en)
Inventor
Anil H Vaidya
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200900139A publication Critical patent/GT200900139A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Addiction (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A METODOS PARA EL TRATAMIENTO DEL ABUSO, ADICCION O DEPENDENCIA DEL ALCOHOL, SOLOS O EN COMBINACION CON UNO O MAS AGENTES CONTRA LA ADDICION PRINCIPALMENTE DEL ALCOHOL QUE RESULTA EN DETERIORO O AFLICCION CLINICAMENTE SIGNIFICATIVA.
GT200900139A 2006-11-28 2009-05-25 Metodos para el tratamiento del abuso, adiccion y dependencia del alcohol GT200900139A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86137506P 2006-11-28 2006-11-28

Publications (1)

Publication Number Publication Date
GT200900139A true GT200900139A (es) 2010-04-29

Family

ID=39345316

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200900139A GT200900139A (es) 2006-11-28 2009-05-25 Metodos para el tratamiento del abuso, adiccion y dependencia del alcohol

Country Status (15)

Country Link
US (1) US20080200492A1 (es)
EP (1) EP2101769B1 (es)
JP (1) JP2010511055A (es)
KR (1) KR20090087042A (es)
CN (1) CN101616669B (es)
AU (1) AU2007325365A1 (es)
CA (1) CA2672273C (es)
CO (1) CO6190520A2 (es)
EA (1) EA200970518A1 (es)
GT (1) GT200900139A (es)
IL (1) IL198792A0 (es)
MX (1) MX2009005640A (es)
NO (1) NO20092078L (es)
WO (1) WO2008067177A2 (es)
ZA (1) ZA200904455B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05002622A (es) 2002-09-09 2005-09-08 Johnson & Johnson Derivados de 1,3,8,-triazaespiro [4.5]decan-4-ona sustituidos con hidroxialquilo utiles para el tratamiento de desordenes mediados por el receptor opioide huerfano.
CN101622254B (zh) * 2006-11-28 2013-05-29 詹森药业有限公司 3-(3-氨基-2-(r)-羟基-丙基)-1-(4-氟-苯基)-8-(8-甲基-萘-1-基甲基)-1,3,8-三氮杂-螺[4.5]癸烷-4-酮的盐
US8741916B2 (en) 2007-04-09 2014-06-03 Janssen Pharmaceutica Nv 1,3,8-trisubstituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as ligands of the ORL-1 receptor
CN104621437A (zh) * 2015-01-21 2015-05-20 胡家宁 一种用于抵抗酒精依赖的食品

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486362A (en) * 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
ID29137A (id) * 1998-07-27 2001-08-02 Schering Corp Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1
WO2002012401A2 (en) 2000-08-07 2002-02-14 Eastman Chemical Company Thermally stable, anthraquinone colorants containing copolymerizable vinyl groups
MXPA05002622A (es) * 2002-09-09 2005-09-08 Johnson & Johnson Derivados de 1,3,8,-triazaespiro [4.5]decan-4-ona sustituidos con hidroxialquilo utiles para el tratamiento de desordenes mediados por el receptor opioide huerfano.

Also Published As

Publication number Publication date
CN101616669B (zh) 2013-05-29
CN101616669A (zh) 2009-12-30
WO2008067177A3 (en) 2008-10-30
EP2101769A2 (en) 2009-09-23
WO2008067177A2 (en) 2008-06-05
US20080200492A1 (en) 2008-08-21
CA2672273C (en) 2016-01-12
EP2101769B1 (en) 2012-10-24
IL198792A0 (en) 2010-02-17
CA2672273A1 (en) 2008-06-05
NO20092078L (no) 2009-08-24
CO6190520A2 (es) 2010-08-19
MX2009005640A (es) 2009-06-05
JP2010511055A (ja) 2010-04-08
EA200970518A1 (ru) 2009-12-30
KR20090087042A (ko) 2009-08-14
ZA200904455B (en) 2010-09-29
AU2007325365A1 (en) 2008-06-05

Similar Documents

Publication Publication Date Title
CR10680A (es) Composiciones de inhibidores de chk1
TW200738263A (en) ANG2 and VEGF inhibitor combinations
AR073563A1 (es) Terapia de combinacion para el tratamiento de diabetes y estados relacionados
CL2008001656A1 (es) Anticuerpo anti-c3b; composicion farmaceutica que lo comprende, y su uso para prevenir o tratar un trastorno asociado con el complemento; kit que lo contiene.
EA201101117A1 (ru) Ингибиторы дпп-4 для лечения диабета у детей
MY160041A (en) Compositions and methods for treating parasitic infections
SV2010003673A (es) Compuestos heterociclicos novedosos y usos de los mismos
BRPI0921685A2 (pt) composição tópica compreendendo uma combinação de pelo menos dois agentes que melhoram a penetração.
BRPI0906549A2 (pt) Bandagens médicas com válvulas e kits contendo as mesmas.
MX338535B (es) Inhibidores de ibat para el tratamiento de enfermeades hepaticas.
CL2011001254A1 (es) Combinacion farmaceutica que comprende un anticuerpo que reconoce especificamente a cd38 y al menos melfalan; y su uso para el tratamiento contra el cancer.
CR20110339A (es) Compuestos útiles para inhibir chk1
CR20110553A (es) Terapia complementaria contra el cáncer
PE20141906A1 (es) Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento
ES2571041T3 (es) Composiciones antimicrobianas
GT201200276A (es) Combinaciones de compuestos activos
ECSP10010697A (es) Inhibidores de dpp-iv para uso en el tratamiento de nafld
GT200800151A (es) Inhibidores de 11-beta-hsd1
BRPI0922301A2 (pt) combinações de inibidor de hsp90
CR20150216A (es) Composiciones y métodos para tratar proteinopatías
CL2008002381A1 (es) Oligonucleotido inmunoestimulador; composicion farmaceutica que lo comprende; y su uso para tratar un trastorno o afeccion en un sujeto, incluyendo cancer.
CO6331298A2 (es) Vacunas contra coccidiosis
MX353964B (es) Agentes terapeuticos y usos de los mismos.
AR068565A1 (es) Composiciones para el tratamiento del cabello
CR11418A (es) Trans-clomifeno para el sindrome metabolico